Furthermore, enhanced ROS production in response to priming with TNF-α and then fMLP-treated neutrophils from the PTPN22 C1858C T1D patients than in those treated with TNF-α or fMLP alone was observed. This evidence concerns the gene PTPN22 and type 1 diabetes mellitus.